PDF(1162 KB)
丙型肝炎肝硬化失代偿患者再代偿的影响因素分析
许丹青, 木唤, 张映媛, 常丽仙, 王远珍, 李卫昆, 董智坚, 张丽华, 程怡菁, 刘立
PDF(1162 KB)
PDF(1162 KB)
丙型肝炎肝硬化失代偿患者再代偿的影响因素分析
Influencing factors for recompensation in patients with decompensated hepatitis C cirrhosis
目的 研究丙型肝炎肝硬化失代偿期患者再代偿发生的影响因素,建立预测模型。 方法 选取2019年1月—2022年12月在昆明市第三人民医院住院诊断为丙型肝炎肝硬化失代偿的患者217例,至少1年之内再住院无门静脉高压相关并发症即再代偿组(n=63),未再代偿者为对照组(n=154)。收集相关临床资料,对可能影响再代偿发生的因素进行单因素及多因素分析。计量资料符合正态分布的两组间比较采用成组t检验,不符合正态分布的两组间比较采用Mann-Whitney U检验。计数资料两组间比较采用χ²检验或Fisher’s确切概率法。运用二元Logistic回归模型分析丙型肝炎肝硬化失代偿患者再代偿发生的影响因素,采用受试者操作特征曲线(ROC曲线)评价模型的预测效能。 结果 217例丙型肝炎肝硬化失代偿期患者中63例发生再代偿(29.03%)。再代偿组与对照组相比,HIV史(χ²=4.566,P=0.034)、部分脾栓塞史(χ²=6.687,P=0.014)、Child-Pugh 评分(χ²=11.978,P=0.003)、腹水分级(χ²=14.229,P<0.001)、Alb(t=4.063,P<0.001)、前白蛋白(Z=-3.077,P=0.002)、HDL(t=2.854,P=0.011)、超敏C反应蛋白(Z=-2.447,P=0.014)、凝血酶原时间(Z=-2.441,P=0.015)、CEA(Z=-2.113,P=0.035)、AFP(Z=-2.063,P=0.039)、CA125(Z=-2.270,P=0.023)、三碘甲状腺素原氨酸(Z=-3.304,P<0.001)、甲状腺素(Z=-2.221,P=0.026)、CD45+(Z=-2.278,P=0.023)、IL-5(Z=-2.845,P=0.004)、TNF-α(Z=-2.176,P=0.030)、门静脉宽度(Z=-5.283,P=0.005)差异均有统计学意义。多因素分析结果显示,部分脾栓塞史(OR=3.064,P=0.049)、HIV史(OR=0.195,P=0.027)、少量腹水(OR=3.390,P=0.017)、AFP(OR=1.003,P=0.004)及门静脉宽度(OR=0.600,P<0.001)为丙型肝炎肝硬化失代偿期发生再代偿的独立影响因素。ROC曲线结果显示HIV史、腹水分级、部分脾脏栓塞史、AFP、门静脉宽度、联合预测模型的曲线下面积依次为0.556、0.641、0.560、0.589、0.745、0.817。 结论 部分脾栓塞史、少量腹水及AFP水平升高的丙型肝炎肝硬化失代偿期患者更容易出现再代偿,有HIV史、门静脉宽度增加的患者不易出现再代偿。
Objective To investigate the influencing factors for recompensation in patients with decompensated hepatitis C cirrhosis, and to establish a predictive model. Methods A total of 217 patients who were diagnosed with decompensated hepatitis C cirrhosis and were admitted to The Third People’s Hospital of Kunming l from January, 2019 to December, 2022 were enrolled, among whom 63 patients who were readmitted within at least 1 year and had no portal hypertension-related complications were enrolled as recompensation group, and 154 patients without recompensation were enrolled as control group. Related clinical data were collected, and univariate and multivariate analyses were performed for the factors that may affect the occurrence of recompensation. The independent-samples t test was used for comparison of normally distributed measurement data between two groups, and the Mann-Whitney U test was used for comparison of non-normally distributed measurement data between two groups; the chi-square test or the Fisher’s exact test was used for comparison of categorical data between two groups. A binary Logistic regression analysis was used to investigate the influencing factors for recompensation in patients with decompensated hepatitis C cirrhosis, and the receiver operating characteristic (ROC) curve was used to assess the predictive performance of the model. Results Among the 217 patients with decompensated hepatitis C cirrhosis, 63 (29.03%) had recompensation. There were significant differences between the recompensation group and the control group in HIV history (χ2=4.566, P=0.034), history of partial splenic embolism (χ2=6.687, P=0.014), Child-Pugh classification (χ2=11.978, P=0.003), grade of ascites (χ2=14.229, P<0.001), albumin (t=4.063, P<0.001), prealbumin (Z=-3.077, P=0.002), high-density lipoprotein (t=2.854, P=0.011), high-sensitivity C-reactive protein (Z=-2.447, P=0.014), prothrombin time (Z=-2.441, P=0.015), carcinoembryonic antigen (Z=-2.113, P=0.035), alpha-fetoprotein (AFP) (Z=-2.063, P=0.039), CA125 (Z=-2.270, P=0.023), TT3 (Z=-3.304, P<0.001), TT4 (Z=-2.221, P=0.026), CD45+ (Z=-2.278, P=0.023), interleukin-5 (Z=-2.845, P=0.004), tumor necrosis factor-α (Z=-2.176, P=0.030), and portal vein width (Z=-5.283, P=0.005). The multivariate analysis showed that history of partial splenic embolism (odds ratio [OR]=3.064, P=0.049), HIV history (OR=0.195, P=0.027), a small amount of ascites (OR=3.390, P=0.017), AFP (OR=1.003, P=0.004), and portal vein width (OR=0.600, P<0.001) were independent influencing factors for the occurrence of recompensation in patients with decompensated hepatitis C cirrhosis. The ROC curve analysis showed that HIV history, grade of ascites, history of partial splenic embolism, AFP, portal vein width, and the combined predictive model of these indices had an area under the ROC curve of 0.556, 0.641, 0.560, 0.589, 0.745, and 0.817, respectively. Conclusion For patients with decompensated hepatitis C cirrhosis, those with a history of partial splenic embolism, a small amount of ascites, and an increase in AFP level are more likely to experience recompensation, while those with a history of HIV and an increase in portal vein width are less likely to experience recompensation.
Hepatitis C / Liver Cirrhosis / Recompensatory / Risk Factors
| 1 |
World Health Organization. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Accountability for the global health sector strategies 2016-2021: actions for impact[M]. Geneva: World Health Organization, 2021.
|
| 2 |
|
| 3 |
Suppl 1
|
| 4 |
YEO YH,
|
| 5 |
|
| 6 |
Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the management of ascites and complications in cirrhosis[J]. J Clin Hepatol, 2017, 33(10): 1847-1863. DOI: 10.3969/j.issn.1001-5256.2017.10.003 .
中华医学会肝病学分会. 肝硬化腹水及相关并发症的诊疗指南[J]. 临床肝胆病杂志, 2017, 33(10): 1847-1863. DOI: 10.3969/j.issn.1001-5256.2017.10.003 .
|
| 7 |
|
| 8 |
Hepatology Branch of Chinese Medical Association. Guidelines on the management of ascites in cirrhosis (2023 version)[J]. Chin J Hepatol, 2023, 31(8): 813-826. DOI: 10.3760/cma.j.cn501113-20230719-00011 .
中华医学会肝病学分会. 肝硬化腹水诊疗指南(2023年版)[J]. 中华肝脏病杂志, 2023, 31(8): 813-826. DOI: 10.3760/cma.j.cn501113-20230719-00011 .
|
| 9 |
|
| 10 |
|
| 11 |
Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. Guideline for the prevention and treatment of hepatitis C (2022 version)[J]. Chin J Clin Infect Dis, 2022, 15(6): 428-447. DOI: 10.3760/cma.j.issn.1674-2397.2022.06.002 .
中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2022年版)[J]. 中华临床感染病杂志, 2022, 15(6): 428-447. DOl: 10.3760/cma.j.issn.1674-2397.2022.06.002.
|
| 12 |
Chinese Society of Hepatology, Chinese Society of Gastroenterology, Chinese Society of Digestive Endoscopology of Chinese Medical Association. Guidelines on the management of esophagogastric variceal bleeding in cirrhotic portal hypertension[J]. J Clin Hepatol, 2023, 9(3): 527-538. DOI: 10.3760/cmaj.cn501113-20220824-00436 .
中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会消化内镜学分会. 肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J]. 临床肝胆病杂志, 2023, 39(3): 527-538. DOI: 10.3760/cmaj.cn501113-20220824-00436 .
|
| 13 |
General Office of National Health Commission. Standard for diagnosis and treatment of primary liver cancer (2022 edition)[J]. J Clin Hepatol, 2022, 38(2): 288-303. DOI: 10.3969/j.issn.1001-5256.2022.02.009 .
国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38(2): 288-303. DOl: 10.3969/j.issn.1001-5256.2022.02.009.
|
| 14 |
|
| 15 |
张婷, 邓优, 康海燕, 等. 恩替卡韦抗病毒治疗的乙型肝炎失代偿期肝硬化患者并发症的再代偿[J]. 中华肝脏病杂志, 2023, 31(7): 692-697. DOI: 10.3760/cma.j.cn501113-20230324-00126 .
|
| 16 |
|
| 17 |
|
| 18 |
|
| 19 |
European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol, 2018, 69(2): 406-460. DOI: 10.1016/j.jhep.2018.03.024 .
|
| 20 |
|
| 21 |
|
| 22 |
|
| 23 |
|
| 24 |
|
| 25 |
|
| 26 |
|
| 27 |
|
| 28 |
|
| 29 |
Suppl 1
|
| 30 |
谢青云, 高峰畏, 雷泽华, 等. 脾动脉非选择性与高选择性插管后部分脾栓塞术在肝硬化继发脾功能亢进患者中的对比研究[J]. 中华肝胆外科杂志, 2021, 27(12): 917-922. DOI: 10.3760/cma.j.cn113884-20210527-00182 .
|
| 31 |
李宗伟, 汪桠琴, 张跃伟. 部分脾动脉栓塞治疗肝硬化脾功能亢进的作用机制[J]. 临床肝胆病杂志, 2023, 39(7): 1714-1720. DOI: 10.3969/j.issn.1001-5256.2023.07.029 .
|
| 32 |
Suppl 1
|
| 33 |
白露, 李庆刚. 部分脾栓塞术对肝硬化脾功能亢进患者炎症反应及凝血功能的影响[J]. 临床研究, 2023, 31(8): 36-38. DOI: 10.12385/j.issn.2096-1278(2023)08-0036-03 .
|
| 34 |
|
| 35 |
|
| 36 |
Committee on HIV/Liver Diseases, Chinese Association of STD and AIDS Prevention and Control; Guangzhou Eighth People’s Hospital, Guangzhou Medical University. Chinese expert consensus on the diagnosis and treatment of HIV co-infection with HBV and HCV[J]. J Clin Hepatol, 2024, 40(6): 1107-1113. DOI: 10.12449/JCH240607 .
中国性病艾滋病防治协会HIV合并肝病专业委员会, 广州医科大学附属市八医院. 中国HIV合并HBV、HCV感染诊治专家共识[J]. 临床肝胆病杂志, 2024, 40(6): 1107-1113. DOI: 10.12449/JCH240607 .
|
| 37 |
|
| 38 |
|
| 39 |
|
| 40 |
|
| 41 |
|
| 42 |
|
| 43 |
赵萍, 翟玉峰, 张怀宏. 血清甲胎蛋白和凝血酶原活动度水平对慢加急性肝衰竭患者预后的预测价值研究[J]. 实用肝脏病杂志, 2017, 20(2):230-231. DOI: 10.3969/j.issn.1672-5069.2017.02.027 .
|
| 44 |
张爱民, 游绍莉, 万志红, 等. 乙型肝炎病毒相关慢加急性肝衰竭患者肝纤维化、肝功能、病毒学指标及甲胎蛋白水平与预后的关系[J]. 临床肝胆病杂志, 2012, 28(6): 459-461. DOI: 10.3969/j.issn.1001-5256.2012.06.016 .
|
许丹青、木唤负责课题设计,资料分析,撰写论文; 张映媛、常丽仙、王远珍、董智坚、张丽华、程怡菁参与收集数据,修改论文;刘立、李卫昆负责拟定写作思路,指导撰写文章并最后定稿。
/
| 〈 |
|
〉 |